Aprea Therapeutics Announces ACESOT-1051 Enrollment Is Accelerating; Clinical Data Presentation Planned For Q4 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
Aprea is testing a new medicine and finding patients for the study faster than expected. When they share results later in 2026, investors will get to see if the medicine is working, which helps people decide what to think about the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.